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INTRODUCTION
Neurodevelopmental disorders of known genetic origin,
like fragile X, Williams, and Down syndromes, can serve as
multidisciplinary, multilevel models for understanding the
neurodevelopmental mechanisms and the origins of other
disorders that are currently defined only at the behav-
ioral level (e.g., dyslexia, attention-deficit/hyperactivity
disorder [ADHD]; autism spectrum disorder [ASD]), with
one critical proviso: they are considered within a truly
developmental framework. Indeed, special emphasis will
be given throughout this chapter on the importance of the
developmental perspective on neurodevelopmental disor-
ders. It is crucial for researchers always to recall that early
genetic modifications—whether deletions, translocations,
duplications, or mutations—are likely to affect neurocog-
nitive functioning from the very outset of development and
to have complex interactions and widespread cascading
effects over time on the resulting phenotype. For example,
research on infants with disorders of known genetic origin
has highlighted the importance of investigating empirically
the very early developmental profile of each syndrome
during infancy, rather than assuming a priori that the cog-
nitive profile in adults is representative of earlier deficits
and abilities (Karmiloff-Smith, 1998; Paterson, Brown,
Gsödl, Johnson, &Karmiloff-Smith, 1999). So, researchers
always need to keep in mind a clear distinction between the
mature, developed, relatively stable brain and the dynami-
cally changing developing brain (Karmiloff-Smith, 2010).
Thus, while genetic disorders can provide unique insights
into how relatively well understood genetic modifications,
molecular pathways, and systems neuroscience influence
cognition, these complex interactions cannot be fully
understood outside their developmental context (Doherty,
Shimi, & Scerif, 2015).
In this chapter, we take the case of one such neurode-
velopmental disorder of known genetic origin, fragile X
syndrome (FXS), to discuss a number of broad issues
that emerge from the comparison with disorders that are
behaviorally defined (see Farran & Karmiloff-Smith, 2012,
for a similar approach using Williams syndrome as the
model disorder). First, we provide a short summary of
the genetic, neurocognitive, and behavioral characteristics
of FXS, with special emphasis on the complex inter-
play between developmental stability and developmental
change. Second, using longitudinal data, we discuss the
ostensibly surprising fact that despite being a monogenetic
disorder, there are wide within-syndrome individual dif-
ferences in the phenotypic outcomes of individuals with
FXS. The longitudinal findings highlight the existence of
within-syndrome developmental trajectories that diverge
over time as well as the importance of identifying both risk
and protective environmental factors that influence these
outcomes. Then we focus on cross-syndrome comparisons
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of the similarities and differences in social and cognitive
problems of children with FXS with those of children
with two behaviorally defined disorders, ADHD and ASD.
We conclude with a strong emphasis on the usefulness of
cross-syndrome comparisons and a discussion of how this
approach can be used as a model for understanding other
genetic disorders in which within-syndrome variability has
not been as thoroughly investigated, particularly within a
longitudinal framework.
THE FRAGILE X GENOTYPE AND PHENOTYPE
Genetically, FXS is caused by the silencing of a single gene
on the X chromosome, and in males who are carriers of
the full mutation it results in an almost complete absence
of the protein product linked to this gene in typical devel-
opment. Phenotypically, the syndrome is associated with
significant attentional, memory, and sociocognitive deficits
that turn out to be more severe than would be predicted
given levels of overall developmental delay. This therefore
makes FXS an ideal model in which to study the effects
of protein networks on the developmental trajectories of
attentional control and memory at multiple levels, from the
cellular to the systems and cognitive neuroscience, and how
they impact on specific cognitive domains such as social
cognition (see Belmonte & Bourgeron, 2006; Bourgeron,
2009; Scerif & Karmiloff-Smith, 2005, for a discussion of
this interdisciplinary approach). Nonetheless, at all levels,
scientists must take into account the developmental con-
straints acting over time if we are to reach a full understand-
ing of the resulting phenotype. In the following paragraphs,
we characterize FXS at these different levels.
Constituting the most common inherited form of intel-
lectual disability, FXS has a prevalence of approximately
1 in every 4,000 males and 1 in every 8,000 females,
although more recent figures estimate a general prevalence
closer to 1 in 2,500 (Crawford, Acuña, & Sherman, 2001;
Hagerman, 2008). It results from a large trinucleotide
CGG repeat expansion in the 5’ untranslated region of
the FMR1 gene at site Xq27.3. While typically developing
individuals usually have approximately 30 CGG repeats
at this site, premutation carriers present with around
55–200 repeats, and individuals with the full mutation
have over 230 repeats (Maddalena et al., 2001). In this
chapter, we will concentrate on full mutation carriers
because of the greater wealth of developmental findings
to date (but see Bourgeois et al., 2009; Cornish, Kogan,
Li, Turk, Jacquemont, & Hagerman, 2009; Cornish et al.,
2008; for fascinating research that now reveals unsuspected
impairments also in premutation carriers, and their devel-
opmental progressions from childhood into young and
late adulthood). The extensive CGG repeat expansion
in full mutation carriers gives rise to epigenetic changes,
such as methylation of the FMR1 gene promoter, and thus
transcriptional silencing of the FMR1 gene itself, which
then results in a reduction of FMRP, the fragile X mental
retardation protein (Verkerk et al., 1991). Because of the
location of the FMR1 on the X chromosome, males are
usually more severely affected than females, the latter being
more resilient because they have two X chromosomes, only
one of which is randomly inactivated (Grigsby, Kemper,
Hagerman, & Myers, 1990).
Phenotypically, individuals with FXS present with
a number of physical features: prominent ears, a long
narrow face, flat feet, joint laxity, and macro-orchidism
(Hagerman, Van Housen, Smith, & McGavran, 1984).
However, while these features are not especially obvious
in early development, they become more evident with
growing maturation. By contrast, developmental delay in
cognitive and motor milestones is more obvious during the
early stages of development, and is often what alerts clin-
icians to the possibility of a neurodevelopmental disorder
in families with newly diagnosed children and no previous
FXS births (Bailey, Skinner, Hatton, & Roberts, 2000).
By contrast, given the inherited nature of the syndrome,
if there is already an older child with FXS in the family,
babies are screened for FXS during fetal or early postnatal
life even in the absence of overt physical signs.
In terms of cellular modifications, FXS results in
numerous anatomical and functional changes at the level
of synaptic connectivity. Post-mortem studies have identi-
fied immature dendritic spines in neurons (Hinton, Brown,
Wisniewski, & Rudelli et al., 1991; Rudelli et al., 1985).
Interestingly from an evolutionary perspective, the FMR1
gene has high conservation across species (Verkerk et al.,
1991), which has made it possible for animal models to
investigate in greater depth the changes that arise from the
loss of FMRP. For example, fmr1 knockout mice develop
dense, immature dendritic spines that are very similar to
those observed in human patients (Comery et al., 1997;
Grossman, Aldridge, Weiler, & Greenough, 2006). Addi-
tional murine research has revealed that FMRP binds
selectively to mRNA in the postsynaptic spaces of den-
dritic spines, thereby repressing synaptic translation by
stalling ribosomal translocation. In typical development,
FMRP de-represses translation in response to synaptic
activity, making the synthesis of crucial synaptic plasticity
proteins possible. The FXS loss of FMRP thus constrains
this response and, because deficits in synaptic plasticity
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correlate with memory and learning problems, it has
been argued that such deficits are the main cause of the
resulting FXS phenotype. In particular, mGluR dependent
long-term depression (LTD), a major form of synaptic
plasticity, is thought to constitute the impaired neurolog-
ical pathway involved in the FXS behavioral symptoms
(Bear, Huber, & Warren, 2004). Furthermore, it has been
demonstrated that mGluR LTD is indeed altered in Fmr1
knockout mice (Huber, Gallagher, Warren, & Bear, 2002),
and that mGluR antagonists can indeed enhance cognitive
and behavioral outcomes (Yan, Rammal, Tranfaglia, &
Bauchwitz, 2005), as well as rescuing immature dendritic
spine morphology (Michalon et al., 2012; Nakamoto,
Nalavadi, Epstein, Narayanan, Bassell, & Warren, 2007).
The successes of the murine intervention studies with
these antagonists have now resulted in relatively successful
clinical trials with human patients using drugs to target
the mGluR LTD pathway (Berry-Kravis et al., 2009).
However, while atypical synaptic function and anatomy
are characteristic of most animal models of FXS, an exam-
ination of different studies that have used Fmr1 knockout
mice reveals that these synaptic phenotypes are in fact tran-
sient and appear developmentally only within short time
windows. This means that their effects are dependent upon
the temporal expression of Fmr1 (Meredith, Dawitz, &
Kramvis, 2012), stressing again the importance of a devel-
opmental perspective on such questions. In sum, although
there is a single and well-understood genetic cause of
FXS, there is wide variation in phenotypic outcome in this
population. This is likely to be due to a combination of
individual temporal expression dynamics together with
differing timing of environmental impacts, something to
which we will turn our attention in a subsequent section.
BRAIN–BEHAVIOR RELATIONS IN FRAGILE X
The investigation of human patients with FXS at the
systems level has yielded interesting links between genes,
brain, and behavior. For example, memory impairments,
particularly working memory, correlate with FMRP lev-
els in FXS as well as with abnormal brain activation in
regions that are critical for memory functions (Menon,
Kwon, Eliez, Taylor, & Reiss, 2000). Moreover, during
attention and impulse control tasks, FMRP also has
been shown to correlate with the atypical recruitment of
dorso-striatal networks (Hoeft, Hernandez, Parthasarathy,
Watson, Hall, & Reiss, 2007; Menon, Leroux, & White,
2004). These studies tend to lend support to the hypothesis
that FMRP is required for the brain to react rapidly in
the service of executive function and working memory
tasks (Lightbody & Reiss, 2009). Additionally, evidence is
accruing to suggest that reduced FMRP is associated with
reduced amygdala volume as well as reduced amygdala
activation during emotion processing tasks (Hessl et al.,
2011). Furthermore, recent research with mouse models
suggests a general neural imbalance between excitation
and inhibition across the whole brain in FXS (D’Hulst
et al., 2006; Gibson, Bartley, Hays, & Huber, 2008). An
exciting area of open research would be to investigate
such an imbalance in humans by measuring the levels of
excitatory and inhibitory neurochemicals, such as GABA
and glutamate, in individuals with FXS using magnetic
resonance spectroscopy. These findings point to a serious
problem in individuals with FXS, because it is known that
the excitatory/inhibitory balance is critical for optimal
functioning at the neural level, both in terms of region
specificity and across developmental time.
Much of the early research on the FXS brain was
done on older children and adults, but recently structural
imaging studies have targeted very young children with
the syndrome (Haas et al., 2009; Hoeft et al., 2008, 2010,
2011). This should in time make possible the much earlier
diagnosis of FXS, identifying in infants precocious neural
markers of atypical brain development. For example, in a
longitudinal study by Hoeft and collaborators (2010) on
1–3-year-old boys with FXS, gray and white matter vol-
umes were measured over a 2-year period. The researchers
identified areas of the brain in which gray matter volumes
were either enlarged (caudate, thalamus, and fusiform gyri)
or reduced (cerebellar vermis), and this held across both
time points, thereby highlighting from a very early point
in development quite stable regional effects in the brains
of individuals in this population. Interestingly, other brain
regions revealed initial gray matter volume that was sim-
ilar to that of typically developing controls (orbital gyri,
basal forebrain, and thalamus), but which subsequently
increased in size in FXS, again stressing the need for a
developmental perspective when considering the atypical
brain (Karmiloff-Smith, 2010). In contrast to gray matter
volumes, white matter volumes of fronto-striatal regions
were greater in FXS compared with typically developing
controls at the first time point, and, in this case, the dif-
ferences did not remain stable but increased over time. In
general, then, these results underscore how structural (and
probably functional) abnormalities within different brain
regions develop differently over time in FXS, reflecting
again time-dependent effects of FMR1 silencing. Such
effects are very similar to those already highlighted in the
context of murine models of FXS.
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COGNITIVE AND BEHAVIORAL PATTERNS
IN FRAGILE X
Individuals with the full FXS mutation present with a
very characteristic cognitive and behavioral profile across
development, despite the existence of strong individual
variation. Males are usually severely impaired intellec-
tually, with an average IQ as low as 41, whereas those
males with incomplete FMR1 inactivation can turn out
to be less affected (Merenstein, Sobesky, Taylor, Riddle,
Tran, & Hagerman, 1996). Males also have quite severe
communication difficulties, including significant language
delay coupled with social awkwardness alongside hyper-
activity, inattention, impulsivity, and anxiety. By contrast,
females—even those with the full mutation—tend to
present with less deficits (due to their unaffected second
X chromosome), often having only moderate and in some
cases no intellectual impairment at all. However, social
problems are frequently part of the female FXS phenotype,
but unlike the co-occurring symptoms in males with FXS,
social impairments in girls and women are more likely to
be accompanied by anxiety or depression (Freund, Reiss,
& Abrams, 1993).
Noteworthy is the fact that subtle behavioral and cogni-
tive delays and deficits are evident in infancy, with parents
becoming concerned about their children’s symptoms on
average as early as 9–13 months of age. However, clinical
confirmation of the atypical developmental pathways often
has to wait until the child is considerably older, that is,
on average around 21–24 months of age, with in many
cases a full diagnosis of FXS not happening until as late as
32–35 months of age (Bailey, Skinner, Hatton, & Roberts,
2000; Bailey, Skinner, & Sparkman, 2003). The early signs
at around 9–12 months of age include decreased object
play, increased leg stereotypies, and atypical postures.
In fact, these quite subtle symptoms have been shown
actually to be able to yield a FXS diagnosis in infancy with
some 73% accuracy (Baranek et al., 2005). Furthermore,
scientific research has revealed that already in infancy,
those with FXS demonstrate poor response inhibition
(Scerif, Cornish, Wilding, Driver, & Karmiloff-Smith,
2004, 2007), poor saccadic eye-movement control (Scerif,
Karmiloff-Smith, Campos, Elsabbagh, Driver, & Cornish,
2005), and prolonged visual attention to objects or what is
known as sticky fixation (Roberts, Hatton, Long, Anello, &
Colombo, 2012). In subsequent FXS development, school
children and adolescents also display poor response inhi-
bition (Sullivan, Hatton, & Hammer, 2007) and atypical
patterns of visual attention (Hooper, Hatton, & Baranek,
2000; Munir, Cornish, & Wilding, 2000a, 2000b). Finally,
executive function is clearly deficient in FXS in childhood,
with concomitant memory impairments (Lanfranchi,
Cornoldi, & Drigo, 2009). All of these characteristic
problems continue into adulthood; nonetheless, the most
serious cognitive impairments have been shown to reside
in executive function and visual-spatial attention in this
syndrome (Cornish, Munir, & Cross, 2001).
INSIGHTS FROM LONGITUDINAL STUDIES
OF FRAGILE X
Attentional control has been a particular area of FXS
research, but hitherto mainly only in cross sectional
designs. Here, we provide data from a longitudinal
approach that yielded deeper insights into the FXS
phenotype. It is indeed longitudinal research that has
highlighted two crucial factors affecting the cognitive
phenotype of individuals with the full mutation. The first
concerns differences in attentional biases that tend to alter
cognitive development from the very outset for children
with this genetic disorder. One important way of targeting
the attentional domain is to compare younger and older
individuals with FXS (Cornish et al., 2007; Scerif et al.,
2004, 2005, 2007), and especially to do so within a longi-
tudinal design (Cornish, Cole, Longhi, Karmiloff-Smith,
& Scerif, 2012; Cornish et al., 2013; Scerif, Longhi, Cole,
Karmiloff-Smith, & Cornish, 2012). The second resides in
the fact that, as we mentioned earlier, even in seemingly
simple monogenic disorders like FXS, the resulting phe-
notype displays significant phenotypic variability across
individuals, as for instance demonstrated by studies of
individual differences in saccadic eye-movement control in
young children with FXS between 12 and 36 months of age
(Scerif et al., 2005). Moreover, variability also exists in how
abilities actually change longitudinally over developmental
time in FXS (Cornish, Cole, Longhi, Karmiloff-Smith,
& Scerif, 2013; Cornish et al., 2012; Scerif et al., 2012).
There is clearly no simple one-to-one mapping between
the mutated gene and the resulting phenotype.
Noteworthy is that fact that studies of neurodevel-
opmental disorders have produced a new emphasis on
theory development, highlighting the need to go beyond
group comparisons and trace instead domain-specific or
even task-specific developmental trajectories, by plotting,
say, numerical or linguistic functioning against individ-
uals’ verbal or nonverbal ability levels (e.g., Thomas,
Annaz, Ansari, Scerif, Jarrold, & Karmiloff-Smith, 2009).
Basically, this involves a new focus on within-syndrome
individual differences. There is indeed a glaring absence
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of studies tracking change over developmental time,
that is, longitudinally. For example, even though striking
attentional difficulties had already been demonstrated in
children with FXS, even when compared with a much
younger typically developing group of children matched
on overall developmental level (Cornish et al., 2007; Scerif
et al., 2004, 2005, 2007), the cross sectional design did
not make it possible to ascertain whether the severity of
attentional difficulties increased over developmental time
or remained stable. This was because the experimental
instruments available to measure attention in younger and
older individuals were often very different in nature and
the outcomes across age were difficult to compare directly.
Moreover, although the FXS cognitive phenotype has been
extensively examined via cross sectional research, far fewer
studies have probed longitudinal changes not only within
attention but also in terms of other sensory and cognitive
domains (e.g., Baranek et al., 2008; Roberts et al., 2009;
Skinner et al., 2005). In other words, studies that simulta-
neously target the FXS phenotype both longitudinally and
in a cross-domain design have been sadly lacking.
However, very recent research using the longitudinal
approach has yielded new insights. For example, although
we know that significant delays in attentional control are
present in boys with FXS, this turns out not to be a case
of developmental arrest. Instead, dynamic trajectories
of delayed development have now been identified. For
example, using a combined cross sectional and prospective
longitudinal design, we examined early profiles of attention
and working memory impairment in FXS (Cornish et al.,
2013). When investigated only in cross sectional designs,
significant weaknesses emerged for boys with FXS, with
no clear improvement over chronological age. By contrast,
when we examined the same issues in a longitudinal design,
we were able to reveal that, although clearly impaired, the
improvements that occurred over time in boys with FXS
paralleled the slope of improvement that we witnessed in
typically developing children. In other words, while cross
sectional approaches would have called on an interpre-
tation of developmental arrest, the longitudinal studies
yielded developmental improvements, albeit delayed com-
pared with TD controls, in both attention and working
memory. While confirming previous cross sectional find-
ings of deficits in attentional control and working memory
compared with what would be expected given their general
level of developmental delay, the Cornish and collabo-
rators’ longitudinal study (2013) additionally revealed
improvements over developmental time that a simple
cross sectional comparison would have masked. The lon-
gitudinal study also measured other aspects of the FXS
cognitive profile (i.e., nonverbal intelligence) and revealed
unique insights that would again have been missed in cross
sectional approaches. For instance, cross sectional studies
of nonverbal IQ scores, measured by the Leiter Interna-
tional Performance Scale–R (Roid & Miller, 1997), had
tended to point to a potential plateau or even decline with
age, whereas our longitudinal trajectories measured with
growth scores (an analogue of raw scores that takes into
account repeated presentations and item difficulty) high-
light instead an albeit small yet significant improvement
over developmental time (Cornish et al., 2012).
What about lower level perceptual rather than cognition-
level functions? Are these unimpaired in FXS? Studies with
adults (Van der Molen et al., 2012) and also with infants
with FXS (Farzin, Whitney, Hagerman, & Rivera, 2008)
suggest that visuospatial attention impairments may in
fact be underpinned by atypical lower level perceptual
abilities. Again, longitudinal data are crucial in evaluating
whether low- level perceptual processing differences do in
fact lead over developmental time to atypical higher level
processing. This yet again highlights the need for more
longitudinal approaches to understanding the complexities
of neurodevelopmental disorders like FXS.
In addition to the aforementioned striking group-level
deficits, clinicians working with individuals with FXS
tend to identify striking individual differences in attention
outcomes, with some individuals much more seriously
affected by inattention than others, even when they have
equivalent levels of IQ. Again, longitudinal studies fol-
lowing sufficiently large samples could start to dissect
the within-syndrome FXS variability, because they enable
researchers to go beyond correlational measures, and ask
instead how within-syndrome variability predicts subse-
quent outcomes. This was indeed our approach in the
longitudinal study referred to above. We measured visual,
auditory, and multimodal attention in young boys with
FXS, aged between 4 and 10 years of age at time 1 and
again 12 months later at time 2 (Scerif et al., 2012). We
also assessed behavior in these boys through standardized
teacher questionnaires targeting dimensions that are rele-
vant to symptoms of ADHD (e.g., Conners Teacher Rating
Scales; Conners, 1997). The results showed that the chil-
dren with FXS attended less well than mental-age matched
typically developing boys and had greater difficulties with
auditory stimuli than with visual ones. In addition, unlike
typically developing children, the boys with FXS did not
benefit from multimodal information. Importantly from
the perspective of individual differences, early visual atten-
tion markers in boys with FXS were significant predictors
of their later ADHD symptomatology, highlighting the
Trim Size: 8.5in x 11in Cicchetti c02.tex V2 - Volume III - 08/26/2015 9:08am Page 73
The Challenges of Comorbidity 73
need to identify the drivers of differing developmental
trajectories for individual children within this seemingly
homogeneous group if measured cross sectionally. Interest-
ingly, while visual attention was a significant longitudinal
predictor ofADHDsymptoms in the boyswithFXS (Scerif
et al., 2012), it was auditory attention that predicted later
symptoms related to ASD (Cornish et al., 2012).
THE CHALLENGES OF COMORBIDITY
Individuals with FXS present with a particularly high risk
for comorbid symptoms, which are found in autism spec-
trum disorder (ASD) and attention-deficit/hyperactivity
disorder (ADHD). Indeed, some 50–90% of patients with
FXS have autistic-like traits such as tactile defensiveness,
poor eye contact, hand flapping, hand biting, and speech
perseveration (Bailey et al., 1998; Baumgardner, Reiss,
Freund, & Abrams, 1995; Kerby & Dawson, 1994). Strik-
ingly, about 25–47% of individuals with FXS actually
meet the diagnosis for ASD (Bailey et al., 1998; Demark,
Feldman & Holden, 2003; Rogers, Wehner, & Hagerman,
2001). Moreover, FXS has been identified as the most
common known genetic cause of ASD, with between 1 and
2%of individuals with ASD having the full FXS mutation
(Devlin & Scherer, 2012).
A similar situation obtains for ADHD. Some 74% of
individuals with FXS meet the criteria for an ADHD diag-
nosis (Backes, Genç, Schreck, Doerfleur, Lehmkuhl, & von
Gontard, 2000), making ADHD themost common comor-
bid condition diagnosed alongside FXS (Tranfaglia, 2011).
Despite these high risk factors for ASD and ADHD, we
have consistently noted in earlier sections that behavioral
outcomes across individuals with FXS are highly variable,
making the investigation of the factors causing individual
differences in these symptoms of both theoretical and
clinical importance. What factors are involved in the devel-
opmental trajectories in many children with FXS to cause
them to present with social and cognitive control problems
similar to those experienced by children diagnosed with
ASD and ADHD, while at the same time there exist other
children with FXS who do not display these particular
socio-cognitive problems? One research advantage stems
from the fact that both FXS and ASD are diagnosed
around the same age and substantially earlier than the
diagnosis of ADHD (usually only diagnosed in the early
school years), making FXS an ideal model for assessing
high risk early in development. Indeed, comorbidity in
disorders of known genetic origin can serve as models for
understanding other disorders that are diagnosed only on
behavioral measures, because the genetic disorders can be
diagnosed much earlier in development. This is not unique
to FXS, of course. Genetic disorders such as Williams
syndrome are also characterized by high risk for ADHD
symptoms (Rhodes, Riby, Matthews, & Coghill, 2011) and
also receive very early diagnosis, often at or shortly after
birth. The same holds for infants with Down syndrome.
Given the early, and possibly perinatal diagnoses, neu-
rodevelopmental disorders like FXS, Williams syndrome
and Down syndrome can be considered models of high
risk for those behaviorally defined disorders. However,
given the developmental unfolding and variability of these
difficulties within and across syndromes, understanding
high risk requires moving away from static snapshots, even
of individual differences, to developmental trajectories.
Furthermore, systematic longitudinal comparisons across
these genetically distinct groups with commonly high risk
for those behavioral symptoms could lead us to understand
the differing developmental trajectories leading to those
symptoms.
Nonetheless, the promise of insights from genetic disor-
ders that, like FXS, are diagnosed early and carry a high
risk for ASD or ADHD is not necessarily straightforward.
Comorbidity With ASD
A first set of questions that obviously must be raised are
the following: Are the comorbid autistic-like traits in FXS
really the same as those existing in individuals with idio-
pathic ASD? Or do they constitute instead the severe end
of a continuum of cognitive impairment and behavioral
difficulties present in more affected individuals? Separat-
ing these two interpretations is not an easy endeavor yet
is clearly critical for the development of behavioral and
pharmacological treatments that address the core impair-
ments in ASD, ADHD, and FXS. Several researchers
have attempted to address this question using behavioral
measures. While some have identified similar profiles of
autistic traits in both individuals with FXS and those with
idiopathic ASD (Bailey et al., 1998), others argue that
behavioral profiles are in fact distinct in the two popu-
lations (Hall, Lightbody, Hirt, Rezvani, & Reiss, 2010;
Kaufmann et al., 2004; McDuffie, Thurman, Hagerman,
& Abbeduto, 2014). For example, McDuffie and colleagues
(2014) designed a study whereby groups of individuals with
idiopathic ASD and individuals with FXS were matched
on three different criteria: (1) on chronological age regard-
less of comorbidity (i.e., some members of the FXS group
met and others did not meet the ASD diagnostic criteria);
(2) on diagnosis (chronological age matches, taking all
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the participants with FXS who had received a comorbid
ASD diagnosis); and (3) on severity (chronological age
together with severity levels of the ASD diagnosis). The
three groups were then compared on the basis of their
scores on the ADI-R, a tool commonly used in the diag-
nosis of ASD, which yields a variety of scores within three
categories: reciprocal social interaction, communication,
and restricted interests/stereotypical behaviors. Compar-
ing idiopathic ASD and comorbid FXS/ASD, the study
identified a number of significant differences in scores, for
instance, for social smiling and complex behaviors. How-
ever, studies based solely on behavior can be problematic,
because they tend to match individuals according to ASD
severity, or ASD diagnostic criteria, which themselves are
behaviorally defined, and then compare groups based on
behaviorally defined ASD symptomatology and measures
of adaptive behaviors. The risk of circularity is obvious.
Circularity can be surmounted by opting for a differ-
ent level of analysis, i.e., neurobiological and molecular
variation between FXS and ASD or ADHD, using both
human and animal models. Taking again the example of
ASD, researchers need to raise the very question of why
genetically defined FXS would lead to ASD-like symp-
toms. Here, the major response stems from research that
has found that many of the targets of FMRP are indeed
the products of genes that have also been implicated in
ASD (Darnell et al., 2011). This has caused scientists to
argue that FXS leads to ASD or autistic-like symptoms
via downstream mechanisms of FMRP. Recent modeling
studies have lent support to this claim by modeling how
FMRP targets not only contribute to an ASD outcome,
but they do so via a number of distinct etiologies. These
include single, rare, highly penetrant disruptions in a
subgroup of embryonically expressed FMRP targets, as
well as multiple less penetrant disruptions with cumulative
effects in a subgroup of FMRP targets up-regulated in
adolescence and adulthood (Steinberg & Webber, 2013).
Such an explanatory framework suggests that FMR1
silencing would put individuals with FXS at higher risk
for comorbid ASD if accompanied by other downstream
hits that are also involved in ASD risk factors. This gives
rise to a further question: why does non-idiopathic ASD,
which may or may not result from genetic disruption
downstream of FMRP, share symptoms with genetically
defined FXS? This is where animal models become critical.
Indeed, molecular work on mice is beginning to shed
light on this issue. Research using a common ASD mouse
model, the NLGN3 KO mouse, has succeeded in creating
the same synaptic phenotype as in FXS (Baudouin et al.,
2012). Thus, despite distinct etiologies, FXS and at least
one example of nonsyndromic ASD share a core neurobi-
ological phenotype, opening the doors to explore shared
therapeutic intervention studies. Moreover, scientists have
argued that the notion of shared genetic and neural mech-
anisms is actually supported also by behavioral findings.
For example, Rogers and collaborators (2001) studied two
subgroups of young children with FXS between the ages
of 21 and 48 months, one of which performed similarly
to children with developmental delay but not ASD, and
the other whose performance was similar to a group with
idiopathic ASD. To explain the subgroup findings, the
authors argue that these differences occur because the
FXS mutation represents high risk for all individuals, but
it is not determinist; additional mutations are likely to
work synergistically with the FXS mutation to result in
comorbid ASD. In spite of the demonstration of shared
genetic and neural mechanisms, there are numerous other
functional and anatomical differences between individuals
with FXS and those with idiopathic ASD, which supports
a contrasting view, that is, that comorbid ASD in FXSmay
be distinct from those in nonsyndromic, idiopathic ASD
(Hazlett et al., 2009). Further in-depth research is clearly
necessary to decide between these competing theories.
Although variation in the behavioral profiles of individuals
with FXS alone, FXS together with comorbid ASD, and
idiopathic ASD obviously complicates the picture, the
investigation of the genetic and cellular mechanisms of
ASD risk in FXS may yield a better understanding of
comorbidity in general as well as of the heterogeneous
presentation of symptoms across individuals, ultimately
resulting in targeted therapeutic interventions based on
biological differences.
Comorbidity With ADHD
Very similar approaches need to be taken to understand
the mechanisms responsible for the presence of hyperactiv-
ity and inattention mechanisms in ADHD and comorbid
FXS/ADHD (Scerif & Baker, in press). Idiopathic ADHD
is associated with both functional and structural abnor-
malities of a distributed right lateralized corticostriatal
network implicated in inhibitory control. Interestingly,
these atypicalities overlap significantly with those impli-
cated by functional imaging studies of inhibitory control
problems in FXS (e.g., Hoeft et al., 2007). Early reports
of localized structural abnormalities have since been com-
plemented by large-scale studies of cortical development
over time (Shaw et al., 2007). Such longitudinal studies
have also pinpointed the differences in prefrontal cortical
thickness across patients with ADHD that tend to predict
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later clinical outcome (Shaw et al., 2006). Functional
abnormalities of these circuits in ADHD have also been
clearly established: fMRI studies using classical inhibitory
control tasks (e.g., gonogo task, stop-signal reaction time)
yield reduced activation of inferior prefrontal cortex and
caudate nucleus compared with healthy age-matched
controls (Durston et al., 2003), a finding that mirrors the
abnormalities found in FXS (Hoeft et al., 2007). Elec-
trophysiological studies also indicate that children with
ADHD differ from controls at multiple time points in the
information processing cascade leading to the inhibition
of a response or when resolving conflict (Liotti, Pliszka,
Perez, Kothmann, & Woldorff, 2005). Again, very similar
findings have emerged from electrophysiological stud-
ies of adolescents and adults with FXS (van der Molen
et al., 2012).
At the level of neurotransmission, the involvement of
striatal circuits in ADHD is strongly supported by the
fact that methylphenidate (MPH), a dopamine reuptake
inhibitor, alleviates symptoms in the majority of affected
cases (Volkow, Wang, Fowler, & Ding, 2005). Interestingly,
MPHhas been shown also to be themost effective pharma-
cological intervention for treating ADHD-like symptoms
in individuals with FXS (Roberts et al., 2011). Intriguingly,
recent findings from genome-wide association studies have
considerably changed prevailing views on which key genes
might be associated with risk for ADHD (Franke, Neale,
& Faraone, 2009). Rather than the expected dopaminergic
candidates, it is genes involved in neurodevelopmental
networks for neurite outgrowth that seem to be more
heavily implicated (Poelmans, Pauls, Buitelaar, & Franke,
2011). This turns out to be consistent with recent evidence
from the study of rare copy-number variants in ADHD,
suggesting that intrinsic neurotransmitter systems, and
more specifically metabotropic glutamatergic pathways,
are likely to be involved in ADHD risk (Elia et al., 2012).
Importantly, these very pathways overlap with those com-
promised in FXS, suggesting at least one neural pathway
of risk for hyperactivity/inattention that is shared between
idiopathic ADHD and FXS.
In summary, the high risk for ADHD- and ASD-like
symptoms in FXS has attracted the attention of scientists
studying those behaviorally defined neurodevelopmen-
tal disorders, because multilevel studies of FXS could
contribute to a much earlier understanding of the develop-
mental trajectories in the normal population that lead to
compromised outcomes in confirmed diagnoses of ADHD
or ASD. The longitudinal assessment of very young chil-
dren with FXS, before their behavioral problems become
consolidated, would be especially helpful in this respect, in
that it could lead to the identification of potential modifi-
able protective factors (e.g., environmental inputs such as
parent-child interaction and teaching practices). However,
this again puts us squarely in the important debate as to
whether ADHD and ASD symptoms in FXS are similar
to or different from those in idiopathic cases of ADHD
and ASD. We argue that a focus on both overlapping
and distinct neural mechanisms may advance this debate,
especially if it also takes into account potential differences
in developmental timing.
RELATIONSHIPS TO THE PRINCIPLES
OF DEVELOPMENTAL PSYCHOPATHOLOGY
Throughout this chapter, we have focused in particular on
a specific neurodevelopmental disorder and its comparison
with other genetic disorders. However, because of their
identified etiology, disorders like FXS, WS and DS offer
inroads into the broader and more general principles of
developmental psychopathology as a whole (Cicchetti &
Toth, 2009). First, their study is increasingly interdisci-
plinary, bridging scientists who work at complementary
levels of enquiry: from cellular neuroscience to systems
neuroscience, developmental and cognitive psychology, as
well as clinical implementation (e.g., see Fung, Quintin,
Haas, & Reiss, 2012, for a review of mechanistic compar-
isons between FXS and WS). Second, work on specific
genetic disorders and their comparison identifies new
challenges for developmental cognitive neuroscientists
working with neurotypical individuals: if they play such
an important role in shaping atypical development (e.g.,
Karmiloff-Smith et al., 2012), how do typical low-level
mechanisms such as attentional biases impact memory and
learning trajectories over developmental time (see Scerif &
Wu, 2014, for emerging implications in the field of typical
attention research)? Third, because the early genetic diag-
nosis increasingly precedes the emergence of childhood
difficulties and it is clear that not all children with dis-
orders like FXS, WS and DS develop full-blown ADHD
or ASD, may offer insights into pathways to protection
and resilience. Fourth, in addition to discovering multi-
level processes leading to maladaptive and adaptive life
span outcomes, researchers in this area now have a range
of interdisciplinary tools to ameliorate poor outcomes.
Although recent efforts have focused on pharmacogenet-
ics (e.g., Jacquemont et al., 2014), there is also growing
interest in complementary effective and syndrome-specific
psychosocial therapies (Turk, 2011). We turn to these
translational implications in a later section.
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FUTURE DIRECTIONS: THE IMPORTANCE
OF LONGITUDINAL COMPARISONS ACROSS
SYNDROMES OF KNOWN GENETIC ORIGIN
Throughout this chapter, we have argued for the impor-
tance of taking a syndrome of known genetic origin to
gain a deeper understanding of those neurodevelopmental
disorders which are currently only defined in terms of
patterns of behavioral deficits. Yet, cross-syndrome com-
parisons amongst genetic syndromes themselves also turn
out to be particularly useful. For example, it is frequently
the case that individuals with different genetic syndromes
end up with the same behavioral scores on a task. Can we
take it that the underlying cognitive and/or neural pro-
cesses are the same? Not necessarily. Indeed, in a series of
cross-syndrome comparisons of genetic syndromes includ-
ing FXS, Down syndrome (DS) and Williams syndrome
(WS), we have revealed different cognitive and neural
processes even when scores fall within the normal range
on standardized tasks such as the Benton or Rivermead
face processing tasks (Karmiloff-Smith et al., 2004). Other
studies, e.g., examining sensitivity to numerical displays
in infants with genetic syndromes such as DS and WS,
revealed different trajectories of saccadic eye movements
even though total looking time scores were equivalent
across the two syndromes (Karmiloff-Smith, 2012). In
comparisons of FXS and WS (e.g., Scerif et al., 2004), we
demonstrated the existence of different patterns underly-
ing equivalent behavioral scores. Such subtle differences
are crucial to inform both theory and intervention, and
underline the importance of syndrome-specific treatment
schedules. In general, comparisons across syndromes yield
subtle impairments that a focus on a single syndrome
would not necessarily reveal. Ultimately, future research in
developmental psychopathology should target prospective
longitudinal designs that directly compare dynamically
changing profiles and trajectories across disorders of
identified genetic etiology, at all their interacting levels.
Detailed prospective work on developmental dynamics at
each level will need to be increasingly complemented by
interdisciplinary collaborations bringing together clini-
cians and researchers working on animal models, systems
neuroscience, and developmental psychology.
TRANSLATIONAL IMPLICATIONS
Translational research has been defined as “research
designed to address how basic behavioral processes inform
the diagnosis, prevention, treatment and delivery of
services for mental illness and, conversely, how knowledge
of mental illness increases our understanding of basic
behavioral processes” (National Advisory Mental Health
Council, 2000, p. iii). The convergence between basic sci-
entists and clinicians in the area of genetic disorders is still
in its infancy. However, we believe that a cross-syndrome
developmental cognitive neuroscience approach will be
pivotal in devising intervention attempts that are truly
syndrome-specific, rather than focused on a collection
of individual behavioral symptoms. To take hyperactiv-
ity and inattention, until now the most commonly used
approach to treat them in the context of FXS has been
stimulant-based treatment (Roberts, Miranda, et al.,
2011). A similar approach has characterized the treatment
of hyperactivity in WS (Rhodes et al., 2011). In contrast,
researchers and clinicians alike have been calling for a
mechanism- and syndrome-specific approach to treatment,
and one that is sensitive to individual and developmental
differences within the spectrum of individuals with FXS
(Jacquemont et al., 2014; Turk, 2011). We believe that
similar translational implications apply to other neurode-
velopmental disorders of identified genetic etiology and
high risk of behavioral difficulties. If these difficulties con-
tinue to be treated as disparate symptoms, rather than the
complex outcomes of multilevel developmental dynamics,
treatment approaches will not be optimized to the specific
needs of individuals with genetic disorders.
CONCLUDING THOUGHTS
In this chapter we have highlighted the importance of
both cross-syndrome comparisons and within-syndrome
variability. Indeed, despite very high risk, FXS is not
of necessity associated with impairment. In fact, some
children with the full FXS mutation function quite well.
This is true in the case not only of females, who have
the additional unaffected X that may act as a protective
factor, but also of some males. So, something protects a
limited number boys from risk, which is why we believe
that the case of young children with a diagnosis of FXS
constitutes an interesting more general model in which
to assess early predictors of risk and resilience, as well as
early predictors of declining or improving neurocognitive
trajectories (Hernandez et al., 2009; Rogers, Wehner, &
Hagerman, 2001). This is particularly true of comorbid-
ity with ASD- and ADHD-like symptomatology. Other
syndromes of known genetic origin (e.g., Williams syn-
drome) have also been used as models for a more general
consideration of neurocognitive disorders (D’Souza et al.,
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2014; Farran & Karmiloff-Smith, 2012; see also Scerif &
Wu, 2014). Cross-syndrome comparisons can also be rich
sources of information at multiple levels of description
(Karmiloff-Smith et al., 2012).
Here, we used the example of fragile X syndrome to
illustrate a number of broad points that emerge from
the study of genetic syndromes. We overviewed what is
known about the FXS genotype and phenotype in terms
of cellular, neural, cognitive, and behavioral aspects of the
syndrome, in particular emphasizing its developmental
nature. Critically, we discussed how recent longitudi-
nal data emphasize the need to focus on variability in
outcomes for affected individuals, even in the face of a
monogenic disorder. As mentioned above, there is indeed
no one-to-onemapping between genetic mutation and phe-
notypic outcome, but rather a complex, time-dependent
pathway across developmental time. The findings on FXS
highlight the need to understand diverging developmen-
tal trajectories, predictors of greater risk, mechanisms
of resilience and environmental protective influences. In
summary, we argue that, because they present biologically
well-dissected information about genetic origin, syndromes
like FXS lend themselves particularly well to study of the
high risk of impairment for common behaviorally defined
disorders, like ADHD and ASD (see Scerif & Baker, in
press, for a review of how this approach might inform
an understanding of ADHD risk). However, to under-
stand trajectories leading to good or poor outcomes, as
well as their overlap or differences across disorders, a
developmentally inspired approach is critical and needs to
go beyond behavioral outcomes and be underpinned by
knowledge of the developmental cognitive neuroscience of
each disorder.
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